Table 2.
Baseline characteristics of the included studies
| Study | Group | Age Mean (SD) |
Sex No. of Female/Male |
Weight Mean (SD) |
BMI Mean (SD) |
SBP Mean (SD) |
FBG Mean (SD) |
Duration– yr. Mean (SD) |
Smoker – no. (%) |
|---|---|---|---|---|---|---|---|---|---|
| Brasnyo et al. | Resveratrol Placebo |
57·9(7·9) 52.5(11.1) |
NA | 90.1(16.3) 105.3(16.7) |
NA | 140(12) 140(17) |
7.9(2.21) 8.8(3.2) |
NA | 0(10) 0(9) |
| Bhatt et al. | Resveratrol Placebo |
56.67(8.91) 57.75(8.71) |
16/12 20/9 |
64.78(9.25) 63.1(9.02) |
24.66(3.57) 24.92(3.05) |
139.71(16.10) 134.51(14.61) |
11.82(3.58) 10.11(2.56) |
7.57(4.56) 6.68(4.7) |
6/28 6/29 |
| Movahed et al. | Resveratrol Placebo |
52.45(6.18) 51.81(6.99) |
17/16 16/17 |
74.26(11.39) 76.60(14.27) |
27.05(3.13) 27.83(4.12) |
129.03(14.91) 129.31(15.16) |
9.76(2.76) 8.40(2.86) |
5.81(1.53) 5.39(1.36) |
7(21.9) 4.(12.9) |
| Goh et al. | Resveratrol Placebo |
55.8(7.3) 56.3(6.0) |
NA | 87.0(26.6) 68.3(13.7) |
29.4(6.8) 24.4(3.6) |
NA | 11.8(2.9) 9.5(1.0) |
9.4(5.3) 9.6(6.3) |
1(10) 2(20) |
| Tome-Carneiro et al. | Resveratrol Placebo |
63(12) 58(10) |
NA | 84(11) 85(16) |
31(5.1) 32(4.5) |
130(16) 129(21) |
8.39(3) 8.22(2) |
NA | 2(22) 8(36) |
| Bashmakov et al. | Resveratrol Placebo |
54.0(10.1) 59.8(6.6) |
6/8 3/7 |
NA | 28(3.5) 29(2.5) |
NA | NA | 15(6.9) 15.2(9.5) |
3(21) 1(10) |
| Thazhath et al. | Resveratrol Placebo |
NA | NA | 81.1(3.7) 81.1(4.3) |
NA | NA | 8.1(0.3) 8.2(0.3) |
NA | NA |
| Timmers et al. | Resveratrol Placebo |
NA | NA | NA | NA | 138(11.8) 141(11.7) |
7.80(1.62) 7.70(1.70) |
NA | NA |
| Javid et al. | Resveratrol Placebo |
49.1(7.4) 50.9(8.9) |
16/5 18/4 |
73.8(10.2) 70.95(11) |
29.3(4.9) 28.3(4.8) |
NA | 8.5(3.1) 9.4(3.0) |
NA | NA |
BMI body mass index, SBP systolic blood pressure, FBG fasting blood glucose